Ask AI
ProCE Banner Activity

From Evidence to Action: Expert Strategies for Individualizing CD38-Based Quadruplet Therapy in Transplant-Eligible NDMM

Slideset

Explore the latest evidence and expert strategies for individualizing CD38-based quadruplet therapy in transplant-eligible NDMM, including novel administration approaches.

Released: March 20, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

Supported by an educational grant from Sanofi Genzyme.

Sanofi Genzyme

Target Audience

This activity is intended for European bone marrow transplant specialists, hematologists, medical oncologists, and other healthcare professionals caring for patients with newly diagnosed multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Develop individualized treatments leveraging anti-CD38 antibody–based quadruplet regimens for patients with newly diagnosed transplant-eligible MM based on current data, approvals, clinical data, expert recommendations, and patient/disease factors

  • Assess the clinical utility of MRD for guiding maintenance therapy and other treatment decisions in the induction setting for patients with transplant-eligible MM

  • Plan supportive care approaches to mitigate the risk of treatment-related adverse events in patients with newly diagnosed MM initiating treatment with anti-CD38 antibody–based quadruplet regimens

  • Appraise emerging data for novel methods of anti-CD38 antibody administration and their implications for reducing treatment burden among patients, caregivers, and HCPs

  • Implement strategies supporting equitable access to anti-CD38 antibody–based quadruplet regimens and supportive care in underserved patients with transplant-eligible MM